Virax Biolabs Group annual shares outstanding
2022
2023
2024
2025
Virax Biolabs Group Shares Outstanding History (VRAX)
Virax Biolabs Group reported 4.3M shares outstanding at the end of fiscal 2025.
View full Virax Biolabs Group company overviewVirax Biolabs Group annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-03-31 | 4.3M | 1.8M | +68.69% |
| 2024 | 2024-03-31 | 2.6M | 1.0M | +65.56% |
| 2023 | 2023-03-31 | 1.6M | −8.4M | −84.42% |
| 2022 | 2022-03-31 | 10.0M | — | — |
Virax Biolabs Group quarterly shares outstanding
Q4.22
Q4.23
Q4.24
Q4.25
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-03-31 | 4.3M | — | — |
| Q4 2024 | 2024-03-31 | 2.6M | — | — |
| Q4 2023 | 2023-03-31 | 1.6M | — | — |
| Q4 2022 | 2022-03-31 | 10.0M | — | — |
Virax Biolabs Group shares outstanding trends
Across the available reported history, Virax Biolabs Group's shares outstanding moved from 2.6M to 4.3M, a change of 1.8M. The latest reported quarter, Q4 2025, shows 4.3M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Virax Biolabs Group filings at SEC.gov ↗